Clinical trials: Sarcoma, Soft-tissue, open to volunteers
Ewing Sarcoma
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
The goal of this clinical research study is to learn if new anticancer drugs or drug combinations can help to control relapsed/refractory ES, DSRCT, or SRCS.
- Trial name
- NCT07781891
- Testing
- LX-101
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Ewing Sarcoma, Rhabdomyosarcoma
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back…
- Conditions
- Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Neuroblastoma
- Trial name
- NYMC195 (NCT04308330)
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York Medical College
Soft Tissue Sarcoma
Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma
The goal of this study is to assess body image, health-related quality of life (QoL), and functioning (gait function, joint function, and walking ability) in patients after resection of localized soft tissue sarcoma (STS) of the…
- Trial name
- NCT06962072
- Testing
- Surgical resection with or without radiotherapy and/or chemotherapy
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Amsterdam UMC
Sarcoma
Sarcoma and Intra-infusion Exercise for Better Outcomes
The main goal of this clinical trial is to determine: 1) the safety and 2) feasibility of moderate-intensity, intra-infusion aerobic exercise in people receiving chemotherapy for non-resected sarcoma and 3) assess whether…
- Trial name
- SEB (NCT07785882)
- Testing
- Exercise
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Kira Bloomquist
Bone Sarcoma, Osteosarcoma
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse.
- Trial name
- REGOMAIN (NCT04698785)
- Testing
- Treatment by regorafenib and best supportive care
- Where
- 16 sites in France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
DLBCL - Diffuse Large B Cell Lymphoma
Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL
This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R …
- Trial name
- NCT07389356
- Testing
- Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
High Grade Sarcoma, Sarcoma
Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial
This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma.
- Trial name
- NCT07650656
- Testing
- Electronic Health Record Review, Fluorescence Imaging, Fluorescence-Guided Surgery
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Myxoid Liposarcoma, Round Cell Liposarcoma
N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
This early phase I trial tests the safety and how well N-803 works in treating patients with synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) that is growing, spreading, or getting worse (progressive) after being…
- Conditions
- Myxoid Liposarcoma, Round Cell Liposarcoma, Synovial Sarcoma
- Trial name
- NCT07261657
- Testing
- Biospecimen Collection, Computed Tomography, Leukapheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Seth Pollack
Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.
- Trial name
- ePPS (NCT06211257)
- Testing
- Dematerialized Personalized Care Plan (ePCP)
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Centre Oscar Lambret
Brain Tumor, Kidney Tumor
Engineering Immune Organoids to Study Pediatric Cancer
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
- Conditions
- Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
- Trial name
- IMMUNEORGANOID (NCT05890781)
- Testing
- Skin biopsy, Fresh tumor sample, Blood sample
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Digestive Cancer, Gynecologic Cancer
Development of Clinical and Biological Database
The BCB is a tool: for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials; to help scientists understand and explain…
- Conditions
- Digestive Cancer, Gynecologic Cancer, Breast Cancer, Sarcoma
- Trial name
- BCBInstitut (NCT03449264)
- Testing
- biological collection
- Where
- France
- Volunteers
- 4,000 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alveolar Soft Part Sarcoma, Leiomyosarcoma
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA.
- Conditions
- Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
- Trial name
- APROMISS (NCT03016819)
- Testing
- AL3818, Dacarbazine, Midazolam 2 mg for CYP3A4 phenotyping
- Where
- 24 sites in United States, China and 3 more
- Volunteers
- 325 people
- Sponsor
- Advenchen Laboratories, LLC
Lymphoma, Primary Effusion
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes.
- Trial name
- NCT05907759
- Testing
- Daratumumab SC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Bone Neoplasm of Vertebral Column, Chordoma
Image Assisted Optimization of Proton Radiation Therapy in Chordomas and Chondrosarcomas
Rationale: Chordomas and chondrosarcomas located in the axial skeleton are malignant neoplasms of bone. These tumors share the same clinical challenges, as the effect of the disease is more a function of their local…
- Conditions
- Bone Neoplasm of Vertebral Column, Chordoma, Chondrosarcoma, Magnetic Resonance Imaging
- Trial name
- CHIPT (NCT04832620)
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Soft Tissue Sarcoma of the Trunk and Extremities
Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma
Phase II, national, multicentric, prospective, randomized (1:1) non-inferiority trial with two parallel groups, incorporating a concurrent observational cohort of eligible non-randomized patients, designed to address critical…
- Trial name
- STARS (NCT07265661)
- Testing
- hypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 1-2 weeks after treatment, hypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 4-6 weeks after treatment
- Volunteers
- 142 people
- Sponsor
- Italian Sarcoma Group
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Dermatofibrosarcoma Protuberans (DFSP)
Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans
This study aims to evaluate the efficacy and safety of toripalimab and anlotinib hydrochloride combined with standard chemotherapy in patients with refractory dermatofibrosarcoma protuberans (DFSP) resistant to imatinib therapy…
- Trial name
- NCT07646080
- Testing
- Toripalimab, Anlotinib, Standard Chemotherapy
- Volunteers
- 20 people
- Sponsor
- Yanjie Zhang, MD